ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center
Research & Reviews 335 results
https://doi.org/10.1182/bloodadvances.2022008615
Blood Advances; Kim WS, Fukuhara N et. al.
Jan 21st, 2023 - Darinaparsin is a novel organic arsenical compound of dimethylated arsenic conjugated to glutathione, with antitumor activity and a mechanism of action markedly different from other available agents. This phase II, nonrandomized, single-arm, open-...
https://clinicaltrials.gov/ct2/show/NCT02520791
Jan 19th, 2023 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...
https://clinicaltrials.gov/ct2/show/NCT03049449
Jan 18th, 2023 - Background: Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed. T cells can be genetically mo...
https://clinicaltrials.gov/ct2/show/NCT03593018
Dec 7th, 2022 - Compared to B-cell Non-Hodgin Lymphoma (NHL), Angioimmunoblastic T-cell Lymphoma (AITL) is more resistant to conventional chemotherapy and is generally associated with an inferior outcome. In case of relapsed of refractory disease, survival durati...
https://clinicaltrials.gov/ct2/show/NCT02561273
Nov 8th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy (CHOEP- cyclophosphamide, doxorubicin [doxorubicin hydrochloride], etoposide, vincristine [vincristine sulfate] and prednisone)...
Guidelines 1 results
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.
Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...
Drugs 1 results see all →
Clinicaltrials.gov 28 results
https://clinicaltrials.gov/ct2/show/NCT02520791
Jan 19th, 2023 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...
https://clinicaltrials.gov/ct2/show/NCT03049449
Jan 18th, 2023 - Background: Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed. T cells can be genetically mo...
https://clinicaltrials.gov/ct2/show/NCT03593018
Dec 7th, 2022 - Compared to B-cell Non-Hodgin Lymphoma (NHL), Angioimmunoblastic T-cell Lymphoma (AITL) is more resistant to conventional chemotherapy and is generally associated with an inferior outcome. In case of relapsed of refractory disease, survival durati...
https://clinicaltrials.gov/ct2/show/NCT02561273
Nov 8th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy (CHOEP- cyclophosphamide, doxorubicin [doxorubicin hydrochloride], etoposide, vincristine [vincristine sulfate] and prednisone)...
https://clinicaltrials.gov/ct2/show/NCT04234048
Oct 26th, 2022 - Fenretinide has been shown to be a relatively safe and effective anticancer therapy; however, dose limiting toxicities due to the excipients used in previous formulations has impeded its therapeutic utility. The product formulation in the current ...
News 71 results
https://www.onclive.com/view/fda-grants-fast-track-designation-to-mt-101-for-cd5-relapsed-refractory-ptcl
Nov 21st, 2022 - The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma (PTCL), according to an announcement from Myeloid Therapeutics, Inc.1...
https://www.onclive.com/view/european-commission-grants-orphan-drug-designation-to-nana-val-for-peripheral-t-cell-lymphoma
Sep 27th, 2022 - The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir (Nana-val) for use as a potential therapeutic option in patients with peripheral T-cell lymphoma (PTCL), according to an announcement from Viracta Th...
https://www.onclive.com/view/tolinapant-displays-encouraging-activity-and-safety-in-relapsed-refractory-ptcl-ctcl
Aug 31st, 2022 - Single-agent tolinapant (ASTX660) generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), according to data from the phase 2 A...
https://www.onclive.com/view/dr-mehta-shah-on-the-variations-of-the-chop-regimen-in-ptcl
Jul 20th, 2022 - Neha Mehta-Shah, MD, MSCI, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, and medical oncologist, Siteman Cancer Center, discusses variations of CHOP-based c...
https://www.onclive.com/view/chop-based-combinations-represent-evolving-standard-of-care-in-frontline-treatment-of-ptcl
Jul 19th, 2022 - CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard of care in the frontline setting for patients with peripheral T-cell lymphoma (PTCL). Although the addition of agents including etoposide and...
